OneSource Specialty Pharma Q1 FY27 Earnings Call: Guides $400M Revenue, 40% EBITDA Margin, RFP Funnel 4X vs. Year Ago

OneSource Specialty Pharma Ltd held its Q1 FY27 earnings call on July 24, 2026. Here's a quick read of what management said — performance, strategy, and the outlook ahead.

Headline Performance & Key Wins

• Rs.4,490 million revenue in Q1 FY 2026-2027, up 37% YoY, driven by broad-based growth across segments.
• Rs.1,233 million EBITDA in Q1 FY 2026-2027, up 29% YoY and 24% QoQ, with sequential margin improvement from product mix (higher drug-device combination contribution).
• 9 new launches and 6 new logos added in Q1 FY 2026-2027; RFP funnel ~4X vs. a year ago, spanning innovators, biosimilars, and animal health.
• 12 inspections completed including 2 surprise FDA audits; no adverse outcomes disclosed.
• Two customers achieved first-to-file status in the US for teriparatide, a potential future commercial opportunity for Onesource.
• Partnership with Formycon for biosimilars manufacturing announced; semaglutide commercial launch in Canada with >40% of India's generic pens market manufactured at their site as of June 2026.

Sterile Days, Lines & Investment Phasing

• Line 1 achieved full revenue contribution in Q1 FY 2026-2027 at 225 sterile days per year; EBITDA is not yet optimal due to upfront Opex for new lines.
• Line 2 expected fully functional from Q2 FY 2026-2027 onwards, adding another 225 sterile days; management targets 475 sterile days in FY 2027-2028 as additional lines are installed.
• ~$100 million capex announced in FY 2025-2026 for DDC and other sites; ~80% committed as of Q1 FY 2026-2027, with no significant additional capex expected in FY 2026-2027 beyond the remaining ~20%.
• Biologics capacity expansion will require additional capex, but management said it will be "significantly lower" than the DDC investment (amount and timing unspecified).
• Softgel greenfield expansion being initiated after current capacity (800M to 2.4B units) is fully utilized; full absorption expected over the next two years (FY 2026-2027 to FY 2027-2028) via CDMO tech transfers from European clients.
• Pre-filled syringes capacity still has significant availability for new customers, contributing to growth to FY 2027-2028 and beyond.

Segment-Level Momentum & Pipeline Visibility

• Drug-device combination (DDC) — semaglutide commercial in Canada, ~40% Indian generic pens market share, new production line online in FY 2026-2027, third line by end of FY 2026-2027, fourth line expected in FY 2027-2028; demand from "who's who of the global generic market."
• Biologics — new contracts: animal health (Q4 FY 2025-2026), large global biosimilar for Micon (Q1 FY 2026-2027), European biotech (FY 2025-2026); commercialization beginning FY 2028-2029 and beyond; management sees need for additional mammalian and microbial capacity given pipeline visibility.
• Injectable (SteriScience) — focused on scarcity plays (penicillins, FDA shortage list); new capabilities: pre-filled syringes and significant lyophilization capacity; H1 FY 2026-2027 shutdown to implement these additions, expected to be a significant contributor to FY 2027-2028 numbers.
• Softgel CDMO — tech transfers from European clients underway, expected to fully absorb 2.4B-unit capacity over the next 12-15 months (through ~Q3 FY 2027-2028); current Rs.550 Cr revenue below earlier aspiration of Rs.800-900 Cr.
• Oncology soft gel NDA launch in Q1 FY 2026-2027 for a top-10 US generic customer; only one other supplier exists, but market is small and near-term revenue contribution expected to be insignificant.
• Order book visibility supports FY 2027-2028 revenue guidance of $400 million, with multiple pillars: DDC, biologics, softgel, and injectable (new capacity available full year FY 2027-2028).

EBITDA Trajectory, Batch Sizes & Mix

• Q1 FY 2026-2027 EBITDA margin improved sequentially, driven by higher contribution from the drug-device combination business; management expects continued quarter-on-quarter improvement in H2 FY 2026-2027 as new lines ramp.
• Batch size expansion from 200 liters to 500 liters underway across most geographies, which would significantly increase output from the same sterile days without additional capacity.
• Business mix shifting toward significantly more Commercial Supply Agreements (CSAs) vs. MSA-stage work, as new capacity enables onboarding of previously constrained customers.
• Opex leverage expected to improve once all lines are operational (targeting 475 sterile days in FY 2027-2028), with upfront costs for new lines currently weighing on EBITDA.
• Injectable margin improvement program focused on valuing long-term supply relationships over low prices, with new capabilities (pre-filled syringes, lyophilization) expected to enhance margins.

Guidance, Milestones & Long-Term Growth

• FY 2027-2028 guidance reiterated — organic revenue of $400 million and EBITDA margins of 40%, with strong visibility on order book and capacity utilization.
• Beyond FY 2027-2028 — biologics segment expected to convert from development MSAs to commercial revenues starting FY 2028-2029; softgel and injectable businesses to contribute as capacities fill.
• EU and US market openings from FY 2028-2029 and FY 2029-2030 onwards, with first-to-file customers; up to FY 2027-2028, guidance relies on emerging markets (excluding Canada).
• Key near-term milestones — capacity addition starting Q2 FY 2026-2027, another expansion towards end of FY 2026-2027; revenue ramp-up from new lines expected in H2 FY 2026-2027.
• Industry tailwinds — management cited over 50% of drug discovery is biologics; US and EU biosimilar guideline changes are driving demand for agile CDMO partners; biologics and drug-device combination are the fastest-growing CDMO segments globally.
• Softgel business has not yet reached the Rs.800-900 Cr revenue aspiration; the new CDMO strategy and tech transfers are expected to close this gap over 12-15 months.

Tariffs, Supply Disruptions & Customer Diversification

• US administration's tariff announcement on generics "after two years" — management noted it is "too early to assess" but based on the pattern of changes and backdowns seen from this administration, no long-term harm to the company or its customers is foreseen.
• Middle East geopolitical tensions (Suez and Strait of Hormuz closures) have caused freight challenges and container constraints, but the impact on Onesource as a CDMO is muted due to ex-works contracts where additional time and cost is borne by customers.
• Dr. Reddy's temporary API manufacturing shutdown caused a temporary disruption in supplies, but management mitigated this through a diversified customer base and ability to pull demand from other customers; capacity remained fully utilized.
• Weight loss generics demand significantly outpaces supply — India's monthly pen volumes rose from less than 2,000 pens to 1,50,000-1,60,000 pens within one year (period to Q1 FY 2026-2027); Canada is still early but showing a clear trajectory.
• Capacity fungibility across all lines allows shifting customers between lines as new capacity comes online; existing customers from Line 1 will be serviced from new lines as Line 2 starts.